Active ingredients can be released with a time delay: OSDrC technology and contract formulation development.
Introduction to release control by OSDrC! The start time of the active ingredient's release and the number of releases can be controlled.
The "OSDrC" technology allows for precise and flexible control of the inner core due to its variable double-structure design, enabling the production of high-quality core tablets and facilitating the development of various new dosage forms. By utilizing accurate inner core positioning technology, it is possible to control the release start time of active ingredients by adjusting the thickness of the outer layer. Additionally, it can accurately position multiple inner cores, making it possible to manufacture tablets with various pulse release characteristics. 【Features】 ■ The thickness of the outer layer allows for free control of drug release. ■ Accurate positioning is possible even with multiple inner cores. ■ Capable of producing tablets with various pulse release characteristics. ◎●◎ Sample Presentation ◎●◎ We will send tablet samples made using OSDrC technology to those who request them. * Data demonstrating that the OSDrC technology can control the release start time and number of releases of active ingredients can be viewed by downloading the PDF below. * For more details about the OSDrC technology, please refer to the OSDrC main brochure or feel free to contact us.
Inquire About This Product
basic information
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（3）
Download All Catalogs
Company information
Sanwa Chemical Research Institute, as a member of the Suzuken Group focused on health creation, provides services aimed at improving the quality of life (QOL) for people who wish for better health, centered around its two main businesses: "pharmaceuticals" and "diagnostic drugs." In the "pharmaceuticals business," we are steadily building a track record with a focus on new drugs in the areas of diabetes and kidney/dialysis-related fields. In the "diagnostic drugs business," we are continuously developing and launching self-blood glucose meters, sensors, and diagnostic drugs for infectious diseases. Furthermore, by adding two more businesses— the "OSDrC (Osudrack) business" utilizing innovative formulation technology and the "contract manufacturing business" with advanced quality control systems— Sanwa Chemical Research Institute continues to evolve further.
